Received Jun 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | Unknown | IM |
The patient received the first dose of RabAvert on 05-Jul-2024, for pre-exposure, and missed the second dose; Case reference number US-BN-2024-002192 is a spontaneous case initially received from pharmacist via Med Communications (reference number USBAV24-1663) on 15-Jul-2024 and concerns a 25-years-old female patient. The patient's medical history and concomitant medication details were not provided. On 05-Jul-2024, the patient was vaccinated with the first dose of RabAvert (batch number: unknown), intramuscularly, at an unknown dose, or route of administration, for pre-exposure prophylaxis. As reported the patient missed the second dose of RabAvert (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to RabAvert. No further information was provided.; Reporter's Comments: A 25-year-old female patient was vaccinated with the first dose of RabAvert for pre-exposure prophylaxis. As reported the patient missed the second dose of RabAvert, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to RabAvert. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 25-year-old female patient was vaccinated with the first dose of RabAvert for pre-exposure prophylaxis. As reported the patient missed the second dose of RabAvert, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to RabAvert. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.